BioCardia (BCDA)
(Real Time Quote from BATS)
$2.82 USD
-0.09 (-3.09%)
Updated Jul 22, 2024 01:02 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BCDA 2.82 -0.09(-3.09%)
Will BCDA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCDA
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
BCDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study
BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates
Other News for BCDA
Biotech Alert: Searches spiking for these stocks today
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
BioCardia announces US Patent Office granted patent on Morph DNA
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
Biotech Alert: Searches spiking for these stocks today